Molecular regulation of interleukin-2 expression by CD28 co-stimulation and anergy

Immunological Reviews

Volumn 165, Issue , 1998, Pages 287-300

  Powell, Jonathan D ^a   Ragheb, Jack A ^a   Kitagawa Sakakida, Satoru ^a   Schwartz, Ronald H ^a,b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR;

CLONAL ANERGY; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 0031725323     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1998.tb01246.x     Document Type: Review

References (86)

1. Dresser DW. Specific inhibition of antibody production: II. Paralysis induced in adult mice by small quantities of protein antigen. Immunology 1962;5:378-388.
2. Lafferty KJ, Cunningham AJ. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci 1975:53:27-42.
3. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology-Cold Spring Harb Symp Quant Biol 1989;54:1-13.
4. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045.
5. Lamb JR, Skidmore BJ, Green N, Chiller JM, Feldmann M. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med 1983;157:1434-1447.
6. Lamb JR, Feldmann M. Essential requirement for major histocompatibility complex recognition in T-cell tolerance induction. Nature 1984;308:72-74.
7. Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987;165:302-319.
8. Quill H, Schwartz RH. Stimulation of normal inducer T cell clones with antigen presented by purified Ia molecules in planar lipid membranes: specific induction of a long-lived state of proliferative nonresponsiveness. J Immunol 1987;138:3704-3712.
9. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 1993;90:6586-6590.
10. Beverly B, Kang SM, Lenardo MJ, Schwartz RH. Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int Immunol 1992;4:661-671.
11. Jenkins MK, Chen CA, Jung G, Mueller DL, Schwartz RH. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J Immunol 1990;144:16-22.
12. Jenkins MK, Ashwell JD, Schwartz RH. Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells. J Immunol 1988;140:3324-3330.
13. Sloan-Lancaster J, Evavold BD, Allen PM. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 1993;363:156-159.
14. Boussiotis VA, Freeman GJ, Gray G, Gribben J, Nadler LM. B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med 1993;178:1753-1763.
15. Bachmann MF, et al. Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation. Immunity 1997;7:549-557.
16. June CH, Ledbetter JA, Gillespie MM, Lindsten T, Thompson CB. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol Cell Biol 1987;7:4472-4481.
17. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993;11:191-212.
18. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996;14:233-258.
19. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991;173:721-730.
20. Freeman GJ, et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993;262:909-911.
21. Tan P, et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993;177:165-73.
22. Umlauf SW, Beverly B, Kang SM, Brorson K, Tran AC, Schwartz RH. Molecular regulation of the IL-2 gene: rheostatic control of the immune system. Immunol Rev 1993;133:177-197.
23. Lindsten T, June CH, Ledbetter JA, Stella G, Thompson CB. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 1989;244:339-343.
24. Caput D, Beutler B, Hartog K, Thayer R, Brown-Shimer S, Cerami A. Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci USA 1986;83:1670-1674.
25. Treisman R. Transient accumulation of c-fos RNA following serum stimulation requires a conserved 5′ element and c-fos 3′ sequences. Cell 1985;42:889-902.
26. Karasuyama H, Melchers F. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol 1988;18:97-104.
27. Henics T, Sanfridson A, Hamilton BJ, Nagy E, Rigby WF. Enhanced stability of interleukin-2 mRNA in MLA 144 cells. J Biol Chem 1994;269:5377-5383.
28. Shaw G, Kamen R. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986;46:659-666.
29. Janeway CA, Travers P. Immunobiology: the immune system in health and disease. London: Current Biology Ltd/Garland Publishing Inc; 1994.
30. Bohjanen PR, Petryniak B, June CH, Thompson CB, Lindsten T. AU RNA-binding factors differ in their binding specificities and affinities. J Biol Chem 1992;267:6302-6309.
31. Bickel M, Iwai Y, Pluznik DH, Cohen RB. Binding of sequence-specific proteins to the adenosine- plus uridine-rich sequences of the murine granulocyte/macrophage colony-stimulating factor mRNA. Proc Natl Acad Sci USA 1992;89:10001-10005.
32. Zhang S, Welch EM, Hogan K, Brown AH, Peltz SW, Jacobson A. Polysome-associated mRNAs are substrates for the nonsense-mediated mRNA decay pathway in Saccharomyces cerevisiae. RNA 1997;3:234-244.
33. Gillis P, Malter JS. The adenosine-uridine binding factor recognizes the AU-rich elements of cytokine, lymphokine, and oncogene mRNAs. J Biol Chem 1991;266:3172-3177.
34. Emmel EA, Verweij CL, Durand DB, Higgins KM, Lacy E, Crabtree GR. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science 1989;246:1617-1620.
35. Chen D, Rothenberg EV. Interleukin 2 transcription factors as molecular targets of cAMP inhibition: delayed inhibition kinetics and combinatorial transcription roles. J Exp Med 1994;179:931-942.
36. Shyu A, Greenberg ME, Belasco JG. The c-fos transcript is targeted for rapid decay by two distinct mRNA degradation pathways. Genes Dev 1989;3:60-72.
37. Wisdom R, Lee W. The protein-coding region of c-myc mRNA contains a sequence that specifies rapid mRNA turnover and induction by protein synthesis inhibitors. Genes Dev 1991;5:232-243.
38. Umlauf SW, Beverly B, Lantz O, Schwartz RH. Regulation of interleukin 2 gene expression by CD28 costimulation in mouse T-cell clones: both nuclear and cytoplasmic RNAs are regulated with complex kinetics. Mol Cell Biol 1995;15:3197-3205.
39. Gibson U. A novel method for real time quantitative RT-PCR. Genome Res 1996;6:995-1001.
40. Brewer G, Ross J. Poly(A) shortening and degradation of the 3′ A+U-rich sequences of human c-myc mRNA in a cell-free system. Mol Cell Biol 1988;8:1697-1708.
41. Bentley DL, Groudine M. A block to elongation is largely responsible for decreased transcription of c-myc in differentiated HL60 cells. Nature 1986;321:702-706.
42. Celano P, et al. Characterization of an endogenous RNA transcript with homology to the antisense strand of the human c-myc gene. J Biol Chem 1992;267:15092-15096.
43. + T cells. Science 1997;276:273-276.
44. Becker JC, Brabletz T, Kirchner T, Conrad CT, Brocker EB, Reisfeld RA. Negative transcriptional regulation in anergic T cells. Proc Natl Acad Sci USA 1995;92:2375-2378.
45. Garda-Sanz JA, Lenig D. Translational control of interleukin 2 messenger RNA as a molecular mechanism of T cell anergy. J Exp Med 1996;184:159-164.
46. Shaw J, Meerovitch K, Bleackley RC, Paetkau V. Mechanisms regulating the level of IL-2 mRNA in T lymphocytes. J Immunol 1988;140:2243-2248.
47. Koeller DM, Koeller DM, Horowitz JA, Casey JL, Klausner RD, Harford JB. Translation and the stability of mRNAs encoding the transferrin receptor and c-fos. Proc Natl Acad Sci USA 1991;88:7778-7782.
48. Maquat LE. When cells stop making sense: effects of nonsense codons on RNA metabolism in vertebrate cells. RNA 1995;1:453-465.
49. Jacobson A, Peltz SW. Interrelationships of the pathways of mRNA decay and translation in eukaryotic cells. Annu Rev Biochem 1996;65:693-739.
50. Fraser JD, Irving BA, Crabtree GR, Weiss A. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 1991;251:313-316.
51. Kitagawa-Sakakida S, Schwartz RH. Multifactor cis-dominant negative regulation of IL-2 gene expression in anergized T cells. J Immunol 1996;157:2328-2339.
52. Carter MS, Li S, Wilkinson MF. A splicing-dependent regulatory mechanism that detects translation signals. EMBO J 1996;15:5965-5975.
53. Li S, Leonard D, Wilkinson MF. T cell receptor (TCR) mini-gene mRNA expression regulated by nonsense codons: a nuclear-associated translation-like mechanism. J Exp Med 1997;185:985-992.
54. Aoufouchi S, Yelamos J, Milstein C. Nonsense mutations inhibit RNA splicing in a cell-free system: recognition of mutant codon is independent of protein synthesis. Cell 1996;85:415-422.
55. Frankel AD. Activation of HIV transcription by Tat. Curr Opin Genet Dev 1992;2:293-298.
56. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG Jr. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 1995;269:1444-1446.
57. Duan DR, et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 1995;269:1402-1406.
58. Williams TM, et al. Identification of a zinc finger protein that inhibits IL-2 gene expression. Science 1991;254:1791-1794.
59. DeSilva DR, Urdahl KB, Jenkins MK. Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation. J Immunol 1991;147:3261-3267.
60. Jenkins MK. The role of cell division in the induction of clonal anergy. Immunol Today 1992;13:69-73.
61. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996;14:483-510.
62. + T cells. Science 1996;271:1272-1276.
63. + T cells. Science 1996;271:1276-1278.
64. Larsen CP, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996;381:434-438.
65. Karnitz LM, Abraham RT. Interleukin-2 receptor signaling mechanisms. Adv Immunol 1996;61:147-199.
66. De Groot RP, Ballou LM, Sassone-Corsi P. Positive regulation of the cAMP-responsive activator CREM by the p70 S6 kinase: an alternative route to mitogen-induced gene expression. Cell 1994;79:81-91.
67. Butscher WG, Powers C, Olive M, Vinson C, Gardner K. Coordinate transactivation of the interleukin-2 CD28 response element by c-Rel and ATF-1/CREB2. J Biol Chem 1998;273:552-560.
68. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-685.
69. Folco EJ, Koren G. Degradation of the inducible cAMP early repressor (ICER) by the ubiquitin-proteasome pathway. Biochem J 1997;328:37-13.
70. Bodor J, Spetz AL, Strominger JL, Habener JF. cAMP inducibility of transcriptional repressor ICER in developing and mature human T lymphocytes. Proc Natl Acad Sci USA 1996;93:3536-3541.
71. Bodor J, Habener JF. Role of transcriptional repressor ICER in cyclic AMP-mediated attenuation of cytokine gene expression in human thymocytes. J Biol Chem 1998;273:9544-9551.
72. Kang SM, Beverly B, Tran AC, Brorson K, Schwartz RH, Lenardo MJ. Transactivation by AP-1 is a molecular target of T cell clonal anergy. Science 1992;257:1134-1138.
73. Boussiotis VA, Freeman GJ, Berezovskaya A, Barber DL, Nadler LM. Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1. Science 1997;278:124-128.
74. Serfling E, Avots A, Neumann M. The architecture of the interleukin-2 promoter: a reflection of T lymphocyte activation. Biochim Biophys Acta 1995;1263:181-200.
75. Jain J, Valge-Archer VE, Rao A. Analysis of the AP-1 sites in the IL-2 promoter. J Immunol 1992;148:1240-1250.
76. Novak TJ, Chen D, Rothenberg EV. Interleukin-1 synergy with phosphoinositide pathway agonists for induction of interleukin-2 gene expression: molecular basis of costimulation. Mol Cell Biol 1990;10:6325-6334.
77. De Groot RP, den Hertog J, Vandenheede JR, Goris J, Sassone-Corsi P. Multiple and cooperative phosphorylation events regulate the CREM activator function. EMBO J 1993;12:3903-3911.
78. Kim TK, Maniatis T. The mechanism of transcriptional synergy of an in vitro assembled interferon-β enhanceosome. Mol Cell 1997;1:119-129.
79. McGuire KL, Iacobelli M. Involvement of Rel, Fos, and Jun proteins in binding activity to the IL- 2 promoter CD28 response element/AP-1 sequence in human T cells. J Immunol 1997;159:1319-1327.
80. Shapiro VS, Truitt KE, Imboden JB, Weiss A. CD28 mediates transcriptional upregulation of the interleukin-2 (IL-2) promoter through a composite element containing the CD28RE and NF-IL-2B AP-1 sites. Mol Cell Biol 1997;17:4051-4058.
81. Della Fazia MA, Servillo G, Sassone-Corsi P. Cyclic AMP signalling and cellular proliferation: regulation of CREB and CREM. FEBS Lett 1997;410:22-24.
82. Masquilier D, Sassone-Corsi P. Transcriptional cross-talk: nuclear factors CREM and CREB bind to AP-1 sites and inhibit activation by Jun. J Biol Chem 1992;267:22460-22466.
83. Barton K, Muthusamy N, Chanyangam M, Fischer C, Clendenin C, Leiden JM. Defective thymocyte proliferation and IL-2 production in transgenic mice expressing a dominant-negative form of CREB. Nature 1996;379:81-85.
84. Kamei Y, et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996;85:403-414.
85. Parry GCN, Mackman N. Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kB-mediated transcription. J Immunol 1997;159:5450-5456.
86. Ashwell JD, Cunningham RE, Noguchi PD, Hernandez D. Cell growth cycle block of T cell hybridomas upon activation with antigen. J Exp Med 1987;165:173-194.